Scientists at the University of Utah in the US have found a compound that blocks pain by targeting a pathway not associated with opioids.
Research in rodents indicates that the benefits continue long after the compound has cleared the body.
The opioid crisis has reached epidemic proportions. Opioids is highly addictive and according to the US Centres for Disease Control and Prevention, 91 Americans die every day from an opioid overdose.
The medical community is in need of alternative therapies that do not rely on the opioid pathways to relieve pain.
Conus regius, a small marine cone snail common to the Caribbean Sea, packs a venomous punch, capable of paralysing and killing its prey.
Researchers found that a compound isolated from snail's venom, Rg1A, acts on a pain pathway distinct from that targeted by opioid drugs.
Using rodent models, the scientists showed that a9a10 nicotinic acetylcholine receptors (nAChR) functions as a pain pathway receptor and that RgIA4 is an effective compound to block this receptor.
The duration of pain relief is long, greatly outlasting the presence of the compound in the animal's system.
The compound works its way through the body in 4 hours, but the scientists found the beneficial effects lingered.
"We found that the compound was still working 72 hours after the injection, still preventing pain," said J Michael McIntosh, professor at the University of Utah.
The duration of the outcome may suggest that the snail compound has a restorative effect on some components of the nervous system.
"Once chronic pain has developed, it is difficult to treat. This compound offers a potential new pathway to prevent pain from developing in the first place and offer a new therapy to patients who have run out of options," he said.
The researchers will continue to the next step of pre-clinical testing to investigate the safety and effectiveness of a new drug therapy.
The research was published in the journal PNAS.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
